Case Report

Decitabine Induced Delayed Cardiomyopathy in Hematologic Malignancy

Pradyumna Agasthi,1 Hemalatha Narayanasamy,1 Dan Sorajja,1 James Slack,2,3 and Farouk Mookadam1,2

1Department of Cardiovascular Diseases, Mayo Clinic, Arizona 85259, USA
2Department of Cardio-Oncology, Mayo Clinic, Arizona 85259, USA
3Department of Internal Medicine, Mayo Clinic, Arizona 85259, USA

Correspondence should be addressed to Pradyumna Agasthi; pradyumna_agasthi@hotmail.com

Received 24 June 2018; Accepted 16 August 2018; Published 30 September 2018

1. Introduction

Decitabine is a pyrimidine analogue of nucleoside cytidine, used for the treatment of myelodysplastic syndromes (MDS) [2–4]. To our knowledge, one case of myocarditis [5] and one case of reversible nonischemic cardiomyopathy [6] from decitabine have been reported, this being the 3rd case.

2. Case Report

A 71-year-old female with a history significant for hypertension, hepatitis B, and hypothyroidism, underwent bone marrow biopsy which showed a hypercellular bone marrow with >90% cellularity and 81% myeloblasts expressing CD 34 and CD 117 markers, confirming a diagnosis of acute myeloid leukemia (AML). Molecular testing showed no evidence for FMS-like tyrosine kinase 3 internal tandem duplication, absence of nucleophosmin1 and KIT exon 8, and 17 mutations, suggesting a lower risk of relapse after chemotherapy. Based on cytogenetic studies, secondary AML was diagnosed.

Given her advanced age, decitabine therapy was commenced. A baseline 2-D transthoracic echocardiogram (TTE) showed normal function with an ejection fraction (EF) of 55–60%. After completing 10 cycles of decitabine, she was noted to have a tachycardia and dyspnea by self-report. She was therefore referred to cardiology with these symptoms in preparation for allogeneic stem cell transplant.

The heart rate was 110/min, and a 2/6 ejection systolic murmur and a loud P2 with an S3 and S4 gallop were heard. Lungs were clear. No jugular venous distension or pedal edema was noted.

Laboratory data is significant for a serum creatinine level of 0.8 mg/dl, estimated glomerular filtration rate of 80 ml/min per 1.73 m², and N-terminal pro-b-type natriuretic peptide level of 517 pg/ml. Her complete blood count showed a white blood cell count of 12.6 × 10⁹/l with greater than 50% blasts, low hemoglobin at 7.8 g/dl, hematocrit value of 25%, large platelet count of 212 × 10⁹/l, and lactate dehydrogenase level of 588 U/l. Serum troponin or creatinine phosphokinase levels were not performed due to a lack of discernibility in patients undergoing chemotherapy for cancer. Echocardiogram showed severe left ventricular systolic dysfunction (EF 28%), mildly abnormal end systolic...
dimension (Figure 1), and a mild reduction in right ventricular systolic function. Global averaged left ventricular longitudinal peak systolic strain was abnormal at −12% (normal more negative than −18%) (Figure 2). Nuclear stress test showed no evidence of coronary disease. Patient was euthyroid at the time of diagnosis.

The patient was diagnosed with New York Heart Association class II and American Heart Association stage B heart failure with reduced ejection fraction. In the absence of any viral illness, toxins, or coronary disease, or concomitant cardiotoxic medication use and known recent normal ejection fraction, the etiology was attributed to decitabine use. The patient was subsequently started on metoprolol succinate 50 mg twice a day and furosemide 20 mg daily. Follow-up echocardiogram 4 weeks later showed no change in the ejection fraction of 28%, but there was mild improvement in the global left ventricular longitudinal peak systolic strain at −15% (improved from −12%).

Figure 1: Transsthoracic echocardiogram of the patient in parasternal long axis view (a) demonstrating an enlarged left ventricular cavity, in apical (four-chamber) view demonstrating a mildly abnormal end systolic (b) and normal end diastolic (c) left ventricular dimension (RV: right ventricle; LV: left ventricle; LA: left atrium; RA: right atrium).

Figure 2: Peak systolic strain pattern in cross-sectional view (a) and longitudinal view (b) demonstrates decrease in left ventricular strain pattern.
proliferation of cancer cells – suppressor genes and other critical genes leads to unopposed patterns leading to promoter hypermethylation and silencing severely altered chromatin structure and methylation patterns. Decitabine is an azanucleoside (AZN), a pyrimidine analogue of cytidine. Cancer cells often exhibit methylation leading to subsequent cellular differentiation. Low dose AZNs have shown optimal inhibition of DNA methylation leading to subsequent cellular differentiation. Decitabine inhibits the action of DNA methyltransferase and restores the normal growth and differentiation of cells. Decitabine was approved in 2006 for high-risk myelodysplastic syndromes of all French-American-British subtypes, chronic myelogenous leukemia, acute myelogenous leukemia, and sickle cell anemia. The common cardiovascular adverse effects ascribed to decitabine include peripheral edema (25%), cardiac murmurs (16%), chest discomfort (7%), and hypotension (6%) [4, 6]. Reports of decitabine-related cardiotoxicity in the literature are scant with a case of myocarditis in a 50-year-old female treated with azacitidine and decitabine for MDS. A reversible nonischemic cardiomyopathy from decitabine in a 75-year-old patient treated with decitabine for AML, presented with heart failure and an EF of 35%. Left heart catheterization showed no obstructive coronary artery disease. With guideline-based heart failure therapy, EF normalised. We present a 71-year-old female treated with AML for 10 cycles presenting with symptoms of EF decline. Table 1 shows the comparison of the previously reported reversible cardiomyopathy.

We present a 71-year-old female treated with AML for 10 cycles presenting with symptoms of EF decline. Table 1 shows the comparison of the previously reported reversible cardiomyopathy.

Approval for the use of decitabine in the treatment of myelodysplastic syndromes is based on two clinical trials. The number of patients in the clinical trials were 170 and 66, respectively. Mean ages of the patients were 68 yrs and 70 yrs. None of the patients participating in the clinical trials developed cardiomyopathy or heart failure. However, no routine echocardiograms or biomarkers were used during the study. The literature suggests that the mechanism for cardiomyopathy is likely myocarditis based on patient coronaries on coronary angiogram and biomarker elevation. The current package insert mentions cardiomyopathy as a potential side effect without the suggestion that it may be attributable to myocarditis.

A recent retrospective study of 111 patients with AML treated with decitabine showed a higher incidence of cardiotoxic side effects in patients with renal dysfunction. New onset heart failure was noted only in patients with renal dysfunction. Our patient developed cardiac dysfunction despite normal kidney function. Contrary to prior reports, our patient had a delayed onset of cardiac dysfunction, which is unique. Clearly, the etiology for cardiac dysfunction with decitabine therapy may be bimodal (early onset versus delayed) and may be due either to hypersensitivity to hypomethylating agents causing myocarditis or to cardiac cell injury. This has yet to be elucidated. We hypothesize that the reason for the lack of cardiac function recovery in our patient might be directly related to the extent or duration of cardiomyocyte injury endured over the prolonged course of decitabine therapy.

The prevalence of chemotherapy-induced cardiomyopathy is increasing because of longer cancer survivorship and multiple new chemotherapeutic regimens where cardiac side effects are understudied. Early detection and prompt treatment is the best strategy. Many of the chemotherapeutic agents have not been studied a priori for cardiotoxicity and are symptom driven. Cardiac dysfunction symptoms may mimic the side effects attributable to the chemotherapy and no standard screening guidelines exist, especially for newer drugs.

Lessons learned from the monoclonal antibody, trastuzumab, which was shown to have a much higher incidence of cardiotoxicity post marketing, need to be applied to newer agents. Well-designed clinical trials involving chemotherapeutic agents or registries for chemotherapeutic agents should be studied for the potential for cardiotoxicity.

### 3. Discussion

#### 3.1. Decitabine

Decitabine is an azanucleoside (AZN), a pyrimidine analogue of cytidine. Cancer cells often exhibit severely altered chromatin structure and methylation patterns leading to promoter hypermethylation and silencing of key tumor suppressor genes. The inactivation of tumor suppressor genes and other critical genes leads to unopposed proliferation of cancer cells.

Low dose AZNs have shown optimal inhibition of DNA methylation leading to subsequent cellular differentiation. Decitabine inhibits the action of DNA methyltransferase and restores the normal growth and differentiation of cells. Decitabine was approved in 2006 for high-risk myelodysplastic syndromes of all French-American-British subtypes, chronic myelogenous leukemia, acute myelogenous leukemia, and sickle cell anemia. The common cardiovascular adverse effects ascribed to decitabine include peripheral edema (25%), cardiac murmurs (16%), chest discomfort (7%), and hypotension (6%) [4, 6].

Reports of decitabine-related cardiotoxicity in the literature are scant with a case of myocarditis in a 50-year-old female treated with azacitidine and decitabine for MDS. A reversible nonischemic cardiomyopathy from decitabine in a 75-year-old patient treated with decitabine for AML, presented with heart failure and an EF of 35%. Left heart catheterization showed no obstructive coronary artery disease. With guideline-based heart failure therapy, EF normalised [6].

We present a 71-year-old female treated with AML for 10 cycles presenting with symptoms of EF decline. Table 1 shows the comparison of the previously reported reversible cardiomyopathy.

Approval for the use of decitabine in the treatment of myelodysplastic syndromes is based on two clinical trials. The number of patients in the clinical trials were 170 and 66, respectively. Mean ages of the patients were 68 yrs and 70 yrs. None of the patients participating in the clinical trials developed cardiomyopathy or heart failure. However, no routine echocardiograms or biomarkers were used during the study. The literature suggests that the mechanism for cardiomyopathy is likely myocarditis based on patient coronaries on coronary angiogram and biomarker elevation [6].

### 4. Conclusion

We present a third case of cardiomyopathy with decitabine used for secondary AML. Since older populations are more prone to chemotherapy-associated cardiomyopathy, screening these vulnerable groups may be helpful for early diagnosis and early treatment.

### Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this article.
References

[1] F. Sorm, A. Piskala, A. Cihak, and J. Vesely, “5-Azacytidine, a new, highly effective cancerostatic,” *Experientia*, vol. 20, no. 4, pp. 202–203, 1964.

[2] P. Fenaux, G. J. Mufti, E. Hellstrom-Lindberg et al., “Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study,” *The Lancet Oncology*, vol. 10, no. 3, pp. 223–232, 2009.

[3] H. Kantarjian, J. P. J. Issa, C. S. Rosenfeld et al., “Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study,” *Cancer*, vol. 106, no. 8, pp. 1794–1803, 2006.

[4] M. Nieto, P. Demolis, E. Béhanzin et al., “The European Medicines Agency review of decitabine (Dacogen) for the treatment of adult patients with acute myeloid leukemia: summary of the scientific assessment of the Committee for Medicinal Products for Human Use,” *The Oncologist*, vol. 21, no. 6, pp. 692–700, 2016.

[5] J. E. Bibault, N. Cambier, J. M. Lemahieu, B. Quesnel, M. Auffret, and C. Rose, “Acute myocarditis induced by hypomethylating agents,” *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*, vol. 29, no. 14, pp. e411–e412, 2011.

[6] C. De, J. Phookan, V. Parikh et al., “Decitabine induced transient cardiomyopathy: a case report,” *Clinical Medicine Insights: Oncology*, vol. 6, 2012.

[7] D. D. von Hoff, M. Slavik, and F. M. Muggia, “5-Azacytidine: a new anticancer drug with effectiveness in acute myelogenous leukemia,” *Annals of Internal Medicine*, vol. 85, no. 2, pp. 237–245, 1976.

[8] P. A. Jones and D. Takai, “The role of DNA methylation in mammalian epigenetics,” *Science*, vol. 293, no. 5532, pp. 1068–1070, 2001.

[9] P. A. Jones and S. M. Taylor, “Cellular differentiation, cytidine analogs and DNA methylation,” *Cell*, vol. 20, no. 1, pp. 85–93, 1980.

[10] P. A. Jones and S. M. Taylor, “Hemimethylated duplex DNAs prepared from 5-azacytidine-treated cells,” *Nucleic Acids Research*, vol. 9, no. 12, pp. 2933–2947, 1981.

[11] J. Diesch, A. Zwick, A. K. Garz, A. Palau, M. Buschbeck, and K. S. Gotze, “A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers,” *Clinical Epigenetics*, vol. 8, no. 1, p. 71, 2016.

[12] H. M. Kantarjian, X. G. Thomas, A. Dmoszynska et al., “Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia,” *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*, vol. 30, no. 21, pp. 2670–2677, 2012.

[13] P. Wijermans, M. Lübbert, G. Verhoef et al., “Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients,” *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*, vol. 18, no. 5, pp. 956–962, 2000.

[14] *Decitabine [Package Insert]*, MGI PHARMA, INC., Bloomington, MN, 2006.

[15] L. B. Levine, J. V. F. Roddy, M. Kim, J. Li, G. Phillips, and A. R. Walker, “A comparison of toxicities in acute myeloid leukemia patients with and without renal impairment treated with decitabine,” *Journal of Oncology Pharmacy Practice*, vol. 24, no. 4, pp. 290–298, 2018.